Radiopeptides for imaging and therapy: A radiant future

Journal of Nuclear Medicine

Volumn 56, Issue 12, 2015, Pages 1809-1812

  Chatalic, Kristell L S ^a   Kwekkeboom, Dik J ^a   De Jong, Marion ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Developments; Imaging; Perspectives; Radionuclide therapy; Radiopeptides

Indexed keywords

ANTINEOPLASTIC AGENT; BISMUTH EDOTREOTIDE BI 213; EVEROLIMUS; FLUORINE 18; FLUORINE BAY 864367 F 18; GALLIUM 68; GALLIUM TETRAXETAN EXENDIN 4 GA 68; INDIUM PENTETIC ACID OCTREOTIDE IN 111; LUTETIUM EDOTREOTIDE LU 177; LUTETIUM OCTREOTATE LU 177; LUTETIUM TETRAXETAN JR 11 LU 177; LUTETIUM TETRAXETAN OCTREOTATE LU 177; RADIOISOTOPE; RADIOPEPTIDE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR; TETRAXETAN; UNCLASSIFIED DRUG; YTRRIUM EDOTREOTIDE Y 90; YTTRIUM TETRAXETAN OCTREOTATE Y 90; FLUORINE; GALLIUM; PEPTIDE;

CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; DRUG UPTAKE; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; LIVER METASTASIS; MEAN RESIDENCE TIME; MEDICAL PROCEDURES; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; PROTEIN TARGETING; RADIATION ABSORPTION; RADIATION DOSE; RADIOACTIVITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANTAGONISTS AND INHIBITORS; METABOLISM; MOLECULAR IMAGING; NEOPLASMS; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; TRENDS;

FLUORINE RADIOISOTOPES; GALLIUM RADIOISOTOPES; HUMANS; MOLECULAR IMAGING; NEOPLASMS; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84958239439     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.161158     Document Type: Review

References (25)

1. Koopmans KP, Glaudemans AW. Rationale for the use of radiolabelled peptides in diagnosis and therapy. Eur J Nucl Med Mol Imaging. 2012;39(suppl 1):S4-S10.
2. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR. Radiopeptide imaging and therapy in Europe. J Nucl Med. 2011;52(suppl 2):42S-55S.
3. Wild D, Fani M, Behe M, et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J Nucl Med. 2011;52:1412-1417.
4. 18F-radiolabeled bombesin analogue BAY 864367 in patients with prostate cancer. J Nucl Med. 2015;56:372-378.
5. Nock BA, Maina T, Krenning EP, de Jong M. "To serve and protect": enzyme inhibitors as radiopeptide escorts promote tumor targeting. J Nucl Med. 2014;55:121-127.
6. 68Ga-DOTA-exendin-4 PET/CT: a pilot study. J Nucl Med. 2015;56:1075-1078.
7. 18F labeling of peptides and proteins. J Labelled Comp Radiopharm. 2014;57:219-223.
8. 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer. J Nucl Med. 2014;55:2050-2056.
9. van Leeuwen FW, de Jong M. Molecular imaging: the emerging role of optical imaging in nuclear medicine. Eur J Nucl Med Mol Imaging. 2014;41:2150-2153.
10. Kuil J, Velders AH, van Leeuwen FW. Multimodal tumor-targeting peptides functionalized with both a radio-and a fluorescent label. Bioconjug Chem. 2010;21:1709-1719.
11. Azhdarinia A, Ghosh P, Ghosh S, Wilganowski N, Sevick-Muraca EM. Dual-labeling strategies for nuclear and fluorescence molecular imaging: a review and analysis. Mol Imaging Biol. 2012;14:261-276.
12. Brand C, Abdel-Atti D, Zhang Y, et al. In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent. Bioconjug Chem. 2014;25:1323-1330.
13. Bison SM, Konijnenberg MW, Melis M, et al. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments. Clin Transl Imaging. 2014;2:55-66.
14. Wild D, Fani M, Fischer R, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55:1248-1252.
15. Dumont RA, Tamma M, Braun F, et al. Targeted radiotherapy of prostate cancer with a gastrin-releasing peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med. 2013;54:762-769.
16. Radojewski P, Dumont R, Marincek N, et al. Towards tailored radiopeptide therapy. Eur J Nucl Med Mol Imaging. 2015;42:1231-1237.
17. Claringbold PG, Turner JH. Pancreatic neuroendocrine tumor control: durable objective response to combination Lu-octreotate-capecitabine-temozolomide radiopeptide chemotherapy. Neuroendocrinology. June 10, 2015 [Epub ahead of print].
18. Claringbold PG, Turner JH. Neuroendocrine tumor therapy with lutetium-177-octreotate and everolimus (NETTLE): a phase I study. Cancer Biother Radiopharm. 2015;30:261-269.
19. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. Eur J Nucl Med Mol Imaging. 2014;41: 2106-2119.
20. 213Bi-substance P [abstract]. Eur J Nucl Med Mol Imaging. 2014;41(suppl 2):S291-S292.
21. 223Ra production via 800 MeV proton irradiation of natural thorium targets. Appl Radiat Isot. 2012;70:2590-2595.
22. Bodei L, Kidd M, Baum RP, Modlin IM. PRRT: defining the paradigm shift to achieve standardization and individualization. J Nucl Med. 2014;55:1753-1756.
23. Strigari L, Konijnenberg M, Chiesa C, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1976-1988.
24. 177Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors. J Nucl Med. 2015;56:505-511.
25. Modlin IM, Oberg K, Taylor A, Drozdov I, Bodei L, Kidd M. Neuroendocrine tumor biomarkers: current status and perspectives. Neuroendocrinology. 2014; 100:265-277.